Article
Author(s):
Tampere, Finland-Both the M2 Single Use microkeratome and the M2 microkeratome with the new 90-?m head (Moria, Antony, France) have been performing well in clinical trials.
Women advised to take part in Dry January to reduce dry eye risk
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Emerging insights into ocular immune-related diseases and treatment options
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
What increased depth of focus can mean to your monofocal IOL patients
Wrapping up another year in eye care: 2024 in review from Ophthalmology Times Europe